Retatrutide 10 mg kit
Also known as · LY-3437943
Retatrutide 10 mg lyophilised vial kit — entry-point research presentation. Includes bac water, syringes, swabs.
Chemistry quick-facts
- CAS
- 2381089-83-2
- Formula
- C221H343N51O66
- MW
- 4729.4 Da
- Length
- 39 aa
- Status
- Investigational (Phase 3, TRIUMPH). Not approved anywhere.
- Purity (HPLC)
- ≥ 99.2%
Mechanism of action
GLP-1 + GIP + glucagon triple-receptor agonism. See the 30 mg kit and pen entries for fuller mechanistic discussion and the full study list.
Research context
The 10 mg format is the smallest lyophilised research-kit presentation of retatrutide. Suitable for initial receptor-binding studies, dose-finding in preclinical models, or use as an analytical reference standard.
Every lot is HPLC + MS verified by Janoshik Analytical before release.
Published studies
A non-exhaustive list of peer-reviewed studies referenced when curating this entry. Click through to the primary source for the full text.
- Jastreboff AM, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2. NEJM.
Active clinical trials
- NCT05929066Phase 3 · Ongoing
TRIUMPH-1
Reconstitution
- Solvent
- Bacteriostatic water for injection (0.9% benzyl alcohol) — included with kit
- Typical volume
- 1 – 2 mL
- · Inject diluent slowly down the side of the vial onto the cake.
- · Swirl gently — do not shake.
- · Solution should be clear and colourless. Discard if not.
Storage
- Lyophilised
- −20 °C, desiccated, protected from light. Stable at 15–25 °C for up to 30 days in transit.
- Reconstituted
- 2–8 °C, original vial, consumed within 4 weeks.
- Shelf life — sealed
- 24 months from date of manufacture when stored lyophilised at −20 °C.
FAQ
Is 10 mg enough for an extended research protocol?+
That depends on the protocol. For short receptor-binding work or analytical reference use, yes. For longer in vitro time-courses, the 30 mg vial or 40 mg pen is more economical on a per-mg basis.
This page summarises the research literature on Retatrutide 10 mg kit for in vitro laboratory investigation only. It is not medical advice, not a treatment recommendation, and not a substitute for a qualified physician. Material is sold for analytical chemistry and cell-culture research, not for human or veterinary administration.
- ResearchRetatrutide 40 mg pen
Retatrutide is a triple agonist at the GLP-1, GIP, and glucagon receptors. The 40 mg pen is the highest-dose presentation in the Omega Grade catalogue
- ResearchRetatrutide 30 mg kit
Retatrutide 30 mg lyophilised vial kit — the mid-dose research presentation. Includes bacteriostatic water, syringes, and swabs.
- BiomarkerHOMA-IR 2.5
HOMA-IR is a calculated index from fasting glucose × fasting insulin. A HOMA-IR of 2.5 sits at the threshold most metabolic research uses for early insulin resistance, often years before HbA1c shifts.
- BiomarkerFasting insulin 12
Fasting insulin of 12 µIU/mL is above the optimal threshold most metabolic research uses (~8). What it indicates, why doctors miss it, and the research literature on early insulin resistance.
- BiomarkerHbA1c 5.7%
HbA1c at 5.7% is the formal threshold the ADA uses to define prediabetes — meaning your average blood glucose has been elevated over the past 2–3 months. What the number means and the research literature on intervention.
- ResearchCagrilintide 10 mg
Cagrilintide is a long-acting amylin analogue most widely investigated in combination with semaglutide under the CagriSema programme. Commonly stacked